Editas Medicine, Inc. (EDIT)
NASDAQ: EDIT · Real-Time Price · USD
3.250
-0.470 (-12.63%)
Oct 27, 2025, 4:00 PM EDT - Market closed
Editas Medicine Revenue
Editas Medicine had revenue of $3.58M in the quarter ending June 30, 2025, with 597.47% growth. This brings the company's revenue in the last twelve months to $38.90M, down -41.97% year-over-year. In the year 2024, Editas Medicine had annual revenue of $32.31M, down -58.64%.
Revenue (ttm)
$38.90M
Revenue Growth
-41.97%
P/S Ratio
7.95
Revenue / Employee
$158,134
Employees
246
Market Cap
292.24M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 32.31M | -45.81M | -58.64% |
| Dec 31, 2023 | 78.12M | 58.41M | 296.32% |
| Dec 31, 2022 | 19.71M | -5.83M | -22.83% |
| Dec 31, 2021 | 25.54M | -65.19M | -71.85% |
| Dec 31, 2020 | 90.73M | 70.20M | 341.93% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
EDIT News
- 12 days ago - Editas Medicine: Three Strikes And It's Out, Or Third Time's The Charm? - Seeking Alpha
- 18 days ago - Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress - GlobeNewsWire
- 21 days ago - Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Editas Medicine, Inc. - Special Call - Seeking Alpha
- 7 weeks ago - Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate - GlobeNewsWire
- 2 months ago - Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate - GlobeNewsWire
- 2 months ago - Editas Medicine to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Editas Medicine Announces Second Quarter 2025 Results and Business Updates - GlobeNewsWire